<!DOCTYPE html>
<html>
<head>
<title>Sonoma Pharmaceuticals, Inc. Post-effective amendment to a registration statement that is not immediately effective upon filing</title>
<link href="https://ir.sonomapharma.com/stylesheets/ir.stockpr.css" rel="stylesheet" type="text/css">
<script type="text/javascript" src="https://ir.sonomapharma.com/javascripts/ir.js"></script>
<link rel="stylesheet" type="text/css" href="https://ir.stockpr.com/stylesheets/xbrl.css">
<script type="text/javascript" src="https://ir.stockpr.com/javascripts/xbrl.min.js"></script>
<script type="text/javascript" src="https://ir.stockpr.com/javascripts/xbrl.js"></script>
</head>
<body>
<style>
body {
font-family: Arial, Helvetica, sans-serif;
font-size: 12px;
color: #454545;
}
</style>
<div class="xbrl-content">
    <h3>Post-effective amendment to a registration statement that is not immediately effective upon filing</h3>
    <div id="xbrl-menu-top">
        <div class="navigation">
            <ul class="xbrl-sf-menu">
                
                    <li>
                        <a class="menu-item " href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/824">Cover</a>
                        <ul class="submenu">
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/824">Document and Entity Information</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item current" href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/825">Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/825">Consolidated Balance Sheets</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/826">Consolidated Balance Sheets (Parenthetical)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/827">Consolidated Statements of Comprehensive Loss</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/828">Consolidated Statements of Changes in Stockholders' Equity</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/829">Consolidated Statements of Cash Flows</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/830">Notes to Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/830">1. Organization and Recent Developments</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/831">2. Liquidity and Financial Condition</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/832">3. Summary of Significant Accounting Policies</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/833">4. Accounts Receivable</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/834">5. Inventories</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/835">6. Prepaid Expenses and Other Current Assets</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/836">7. Property and Equipment</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/837">8. Investment in Ruthigen, Inc.</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/838">9. Accrued Expenses and Other Current Liabilities</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/839">10. Long-Term Debt</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/840">11. Derivative Liability</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/841">12. Commitments and Contingencies</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/842">13. Stockholders' Equity</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/843">14. Stock-Based Compensation</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/844">15. Income Taxes</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/845">16. Employee Benefit Plan</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/846">17. Segment and Geographic Information</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/847">18. Subsequent Events</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/848">Accounting Policies</a>
                        <ul class="submenu">
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/848">3. Summary of Significant Accounting Policies (Policies)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/849">Notes Tables</a>
                        <ul class="submenu">
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/849">3. Summary of Significant Accounting Policies (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/850">4. Accounts Receivable (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/851">5. Inventories (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/852">6. Prepaid Expenses and Other Current Assets (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/853">7. Property and Equipment (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/854">8. Investment in Ruthigen, Inc. (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/855">9. Accrued Expenses and Other Current Liabilities (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/856">11. Derivative Liability (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/857">12. Commitments and Contingencies (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/858">14. Stock-Based Compensation (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/859">15. Income Taxes (Tables)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/860">17. Segment and Geographic Information (Tables)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/861">Notes Details</a>
                        <ul class="submenu">
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/861">1. Organization and Recent Developments (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/862">2. Liquidity and Financial Condition (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/863">3. Summary of Significant Accounting Policies (Details - Fair Value)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/864">3. Summary of Significant Accounting Policies (Details-Useful lives)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/865">3. Summary of Significant Accounting Policies (Details-Earnings per share)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/866">3. Summary of Significant Accounting Policies (Details-Antidilutive shares)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/867">3. Summary of Significant Accounting Policies (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/868">4. Accounts Receivable (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/869">4. Accounts Receivable (Details-Doubtful accounts)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/870">5. Inventories (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/871">6. Prepaid Expenses and Other Current Assets (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/872">7. Property and Equipment (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/873">7. Property and Equipment (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/874">8. Investment in Ruthigen (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/875">8. Investment in Ruthigen (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/876">9. Accrued Expenses and Other Current Liabilities (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/877">10. Long-Term Debt (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/878">11. Derivative Liability (Details-Warrant information)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/879">11. Derivative Liability (Details-Level 3)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/880">12. Commitments and Contingencies (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/881">12. Commitments and Contingencies (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/882">13. Stockholders' Equity (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/883">14. Stock-Based Compensation (Details-Plans)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/884">14. Stock-Based Compensation (Details-Option activity)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/885">14. Stock-Based Compensation (Details-Stock-based compensation)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/886">14. Stock-Based Compensation (Details-Assumptions)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/887">14. Stock-Based Compensation (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/888">15. Income Taxes (Details-Deferred taxes)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/889">15. Income Taxes (Details-Income tax expense)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/890">15. Income Taxes (Details-Reconciliation of tax rate)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/891">15. Income Taxes (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/892">16. Employee Benefit Plan (Details Narrative)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/893">17. Segment and Geographic Information (Details)</a></li>
                                                            <li><a href="https://ir.sonomapharma.com/all-sec-filings/xbrl_doc_only/894">17. Segment and Geographic Information (Details Narrative)</a></li>
                                                    </ul>
                    </li>
                            </ul>
        </div>
    </div>
    <div class="spr-xbrl-document">
        <h4>Consolidated Statements of Comprehensive Loss</h4>
                <div style="clear:both;"></div>
    </div>
</div>
</body>
</html>